Cognitive function in patients with malignant lymphoma undergoing chemotherapy -Relation to physical and mental function and treatment-related factors-

Cognitive function in patients with malignant lymphoma undergoing chemotherapy -Relation to physical and mental function and treatment-related factors- - Cognitive function in patients with malignant lymphoma undergoing chemotherapy -Relation to physical and mental function and treatment-related factors-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000044892

Enrollment

100

Registered

2021-07-17

Start date

2021-09-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with malignant lymphoma who are hospitalized Age: 20 years or older at the time of obtaining consent Performance Status (PS) of 3 or higher

Exclusion criteria

Exclusion criteria: When the attending physician deems it inappropriate Patients with psychiatric disorders Patients with serious cardiac, respiratory, hepatic or renal dysfunction Patients with malignant lymphoma with primary central nervous system or brain lesions Patients with a history of dementia Patients with a history of central nervous system disease

Design outcomes

Primary

Measure	Time frame
The Montreal Cognitive Assessment-japan	—

Secondary

Measure	Time frame
Age, gender, Treatment period, PS, IADL, anxiety, fatigue, pain, grip strength, Timed Up and Go Test	—

Countries

Japan

Contacts

Public Contactryota yamaguchi

Nagasaki University Hospital Rehabilitation Dept.

r-yamaguchi@nagasaki-u.ac.jp0958197200

Outcome results